| Harris Zamir, MD | |
|
2301 Holmes St, Kansas City, MO 64108-2640 | |
| (816) 404-1000 | |
| Not Available |
| Full Name | Harris Zamir |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 6 Years |
| Location | 2301 Holmes St, Kansas City, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861999484 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 2021022310 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Truman Medical Center Hospital Hill | Kansas city, MO | Hospital |
| Truman Medical Center Lakewood | Kansas city, MO | Hospital |
| Cameron Regional Medical Center | Cameron, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Health Physicians | 1153235825 | 301 |
| Cameron Regional Medical Center Inc | 5092622001 | 58 |
News Archive
Genentech, Inc., Biogen Idec and Roche have announced that the New England Journal of Medicine published the results of a Phase IIa study showing that two doses of Rituxan® (Rituximab), administered two weeks apart, improved symptoms in patients with moderate-to-severe rheumatoid arthritis (RA) for up to 48 weeks when combined with methotrexate (MTX), compared to MTX alone.
New research from Taiwan shows that severe sleep apnea is a risk factor for developing diabetic macular edema, a complication of diabetes that can cause vision loss or blindness. Diabetic macular edema was also more difficult to treat in patients with severe sleep apnea.
Men and women with elevated blood pressure who make healthy lifestyle changes and sustain them for up to a year and a half can substantially reduce their rates of high blood pressure and potentially decrease their heart disease risk.
Researchers have made rapid advances in understanding how to manipulate the immune system safely to destroy cancer cells. Adoptive transfer of haploidentical natural killer cells has shown promise as a treatment option to target and kill cancer cells in a less toxic way than conventional therapies. Now for the first time, scientists will combine NK cell therapy with an immunocytokine to target children with relapsed/refractory disease including those with bulky tumors.
A study of more than 1,000 motor vehicle accident survivors published in JNeurosci reveals a common variant in a gene involved in the stress response that increases vulnerability to developing chronic pain. Addressing the interaction between this genetic variant and post-traumatic stress may represent a supplemental or alternative to treatment with addictive opioids.
› Verified 7 days ago
| Entity Name | University Health Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669456257 PECOS PAC ID: 1153235825 Enrollment ID: O20031117000701 |
News Archive
Genentech, Inc., Biogen Idec and Roche have announced that the New England Journal of Medicine published the results of a Phase IIa study showing that two doses of Rituxan® (Rituximab), administered two weeks apart, improved symptoms in patients with moderate-to-severe rheumatoid arthritis (RA) for up to 48 weeks when combined with methotrexate (MTX), compared to MTX alone.
New research from Taiwan shows that severe sleep apnea is a risk factor for developing diabetic macular edema, a complication of diabetes that can cause vision loss or blindness. Diabetic macular edema was also more difficult to treat in patients with severe sleep apnea.
Men and women with elevated blood pressure who make healthy lifestyle changes and sustain them for up to a year and a half can substantially reduce their rates of high blood pressure and potentially decrease their heart disease risk.
Researchers have made rapid advances in understanding how to manipulate the immune system safely to destroy cancer cells. Adoptive transfer of haploidentical natural killer cells has shown promise as a treatment option to target and kill cancer cells in a less toxic way than conventional therapies. Now for the first time, scientists will combine NK cell therapy with an immunocytokine to target children with relapsed/refractory disease including those with bulky tumors.
A study of more than 1,000 motor vehicle accident survivors published in JNeurosci reveals a common variant in a gene involved in the stress response that increases vulnerability to developing chronic pain. Addressing the interaction between this genetic variant and post-traumatic stress may represent a supplemental or alternative to treatment with addictive opioids.
› Verified 7 days ago
| Entity Name | Cameron Regional Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811905375 PECOS PAC ID: 5092622001 Enrollment ID: O20040113000619 |
News Archive
Genentech, Inc., Biogen Idec and Roche have announced that the New England Journal of Medicine published the results of a Phase IIa study showing that two doses of Rituxan® (Rituximab), administered two weeks apart, improved symptoms in patients with moderate-to-severe rheumatoid arthritis (RA) for up to 48 weeks when combined with methotrexate (MTX), compared to MTX alone.
New research from Taiwan shows that severe sleep apnea is a risk factor for developing diabetic macular edema, a complication of diabetes that can cause vision loss or blindness. Diabetic macular edema was also more difficult to treat in patients with severe sleep apnea.
Men and women with elevated blood pressure who make healthy lifestyle changes and sustain them for up to a year and a half can substantially reduce their rates of high blood pressure and potentially decrease their heart disease risk.
Researchers have made rapid advances in understanding how to manipulate the immune system safely to destroy cancer cells. Adoptive transfer of haploidentical natural killer cells has shown promise as a treatment option to target and kill cancer cells in a less toxic way than conventional therapies. Now for the first time, scientists will combine NK cell therapy with an immunocytokine to target children with relapsed/refractory disease including those with bulky tumors.
A study of more than 1,000 motor vehicle accident survivors published in JNeurosci reveals a common variant in a gene involved in the stress response that increases vulnerability to developing chronic pain. Addressing the interaction between this genetic variant and post-traumatic stress may represent a supplemental or alternative to treatment with addictive opioids.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Harris Zamir, MD 2301 Holmes St, Kansas City, MO 64108-2640 Ph: () - | Harris Zamir, MD 2301 Holmes St, Kansas City, MO 64108-2640 Ph: (816) 404-1000 |
News Archive
Genentech, Inc., Biogen Idec and Roche have announced that the New England Journal of Medicine published the results of a Phase IIa study showing that two doses of Rituxan® (Rituximab), administered two weeks apart, improved symptoms in patients with moderate-to-severe rheumatoid arthritis (RA) for up to 48 weeks when combined with methotrexate (MTX), compared to MTX alone.
New research from Taiwan shows that severe sleep apnea is a risk factor for developing diabetic macular edema, a complication of diabetes that can cause vision loss or blindness. Diabetic macular edema was also more difficult to treat in patients with severe sleep apnea.
Men and women with elevated blood pressure who make healthy lifestyle changes and sustain them for up to a year and a half can substantially reduce their rates of high blood pressure and potentially decrease their heart disease risk.
Researchers have made rapid advances in understanding how to manipulate the immune system safely to destroy cancer cells. Adoptive transfer of haploidentical natural killer cells has shown promise as a treatment option to target and kill cancer cells in a less toxic way than conventional therapies. Now for the first time, scientists will combine NK cell therapy with an immunocytokine to target children with relapsed/refractory disease including those with bulky tumors.
A study of more than 1,000 motor vehicle accident survivors published in JNeurosci reveals a common variant in a gene involved in the stress response that increases vulnerability to developing chronic pain. Addressing the interaction between this genetic variant and post-traumatic stress may represent a supplemental or alternative to treatment with addictive opioids.
› Verified 7 days ago
Subashis Paul, M.D. Hospitalist Medicare: Medicare Enrolled Practice Location: 2301 Main St, Kansas City, MO 64108 Phone: 816-395-3558 | |
Tyler Porter, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 4401 Wornall Rd, Kansas City, MO 64111 Phone: 816-932-0340 | |
Christine M. Sankpill, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 4401 Wornall Rd, Kansas City, MO 64111 Phone: 816-932-0340 Fax: 816-932-3148 | |
Anuhya Caipa Young, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 4401 Wornall Rd, Kansas City, MO 64111 Phone: 816-932-0340 Fax: 816-932-3148 | |
David A Wooldridge, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 4401 Wornall Rd, Kansas City, MO 64111 Phone: 816-932-0340 Fax: 816-932-3148 | |
Peter Lebourveau, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 4401 Wornall Rd, Kansas City, MO 64111 Phone: 816-932-0340 Fax: 816-932-3148 | |
David C Hermanns, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2301 Holmes St, Kansas City, MO 64108 Phone: 816-404-1000 |